Egetis Therapeutics AB (publ)

OM:EGTX Stock Report

Market Cap: SEK 1.7b

Egetis Therapeutics Future Growth

Future criteria checks 5/6

Egetis Therapeutics is forecast to grow earnings and revenue by 90% and 70.3% per annum respectively. EPS is expected to grow by 103.4% per annum. Return on equity is forecast to be 9.6% in 3 years.

Key information

90.0%

Earnings growth rate

103.4%

EPS growth rate

Biotechs earnings growth45.3%
Revenue growth rate70.3%
Future return on equity9.6%
Analyst coverage

Low

Last updated23 Aug 2024

Recent future growth updates

Recent updates

Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?

Aug 20
Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

May 26
Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate

Dec 21
We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate

Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?

Jun 07
Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?

Is Egetis Therapeutics AB (publ) (STO:EGTX) Trading At A 30% Discount?

Jan 19
Is Egetis Therapeutics AB (publ) (STO:EGTX) Trading At A 30% Discount?

Egetis Therapeutics AB (publ) (STO:EGTX) Is Expected To Breakeven In The Near Future

Mar 22
Egetis Therapeutics AB (publ) (STO:EGTX) Is Expected To Breakeven In The Near Future

What Type Of Returns Would Egetis Therapeutics'(STO:EGTX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Feb 15
What Type Of Returns Would Egetis Therapeutics'(STO:EGTX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Earnings and Revenue Growth Forecasts

OM:EGTX - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026429128184914
12/31/2025323-61-86-225
12/31/202468-313-340-2903
6/30/202471-319-247-247N/A
3/31/202463-327-254-254N/A
12/31/202358-327-278-278N/A
9/30/202331-318-299-299N/A
6/30/202324-286-249-249N/A
3/31/202322-240-220-220N/A
12/31/202223-194-173-173N/A
9/30/202220-148-137-137N/A
6/30/202221-113-125-125N/A
3/31/202242-114-128-128N/A
12/31/202138-104-130-130N/A
9/30/202140-147-143-143N/A
6/30/202136-153-137-137N/A
3/31/202133-155-133-133N/A
12/31/202041-178-135-135N/A
9/30/202053-127-124-124N/A
6/30/202056-134-134-134N/A
3/31/202039-127-127-127N/A
12/31/201983-61-63-63N/A
9/30/201977-61-54-54N/A
6/30/201977-48-38-38N/A
3/31/201982-46-39-39N/A
12/31/201828-85-81-81N/A
9/30/201831-95-106-106N/A
6/30/201824-103-97-97N/A
3/31/201814-91N/A-90N/A
12/31/201714-88N/A-87N/A
9/30/2017N/A-67N/A-51N/A
6/30/20170-48N/A-49N/A
3/31/2017N/A-44N/A-41N/A
12/31/2016N/A-38N/A-36N/A
9/30/2016N/A-36N/A-36N/A
6/30/2016N/A-39N/A-38N/A
3/31/2016N/A-39N/A-44N/A
12/31/2015N/A-44N/A-51N/A
9/30/2015N/A-53N/A-55N/A
6/30/2015N/A-53N/A-52N/A
3/31/2015N/A-54N/A-47N/A
12/31/2014N/A-48N/A-41N/A
9/30/2014N/A-38N/A-34N/A
6/30/2014N/A-31N/A-31N/A
3/31/2014N/A-24N/A-25N/A
12/31/2013N/A-26N/A-28N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EGTX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.1%).

Earnings vs Market: EGTX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: EGTX is expected to become profitable in the next 3 years.

Revenue vs Market: EGTX's revenue (70.3% per year) is forecast to grow faster than the Swedish market (1.1% per year).

High Growth Revenue: EGTX's revenue (70.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: EGTX's Return on Equity is forecast to be low in 3 years time (9.6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y